Flotetuzumab for the Treatment of Pediatric Recurrent or Refractory Acute Myeloid Leukemia

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

January 22, 2020

Primary Completion Date

September 30, 2022

Study Completion Date

September 22, 2025

Conditions
Recurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia
Interventions
DRUG

Cytarabine

Given IT

BIOLOGICAL

Flotetuzumab

Given IV

Trial Locations (19)

10032

NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York

15224

Children's Hospital of Pittsburgh of UPMC, Pittsburgh

19104

Children's Hospital of Philadelphia, Philadelphia

20010

Children's National Medical Center, Washington D.C.

30329

Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta

35233

Children's Hospital of Alabama, Birmingham

38105

Saint Jude Children's Research Hospital, Memphis

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

46202

Riley Hospital for Children, Indianapolis

48109

C S Mott Children's Hospital, Ann Arbor

55455

University of Minnesota/Masonic Cancer Center, Minneapolis

60611

Lurie Children's Hospital-Chicago, Chicago

63110

Washington University School of Medicine, St Louis

77030

Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston

80045

Children's Hospital Colorado, Aurora

90027

Children's Hospital Los Angeles, Los Angeles

92868

Children's Hospital of Orange County, Orange

94158

UCSF Medical Center-Mission Bay, San Francisco

98105

Seattle Children's Hospital, Seattle

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Children's Oncology Group

NETWORK

NCT04158739 - Flotetuzumab for the Treatment of Pediatric Recurrent or Refractory Acute Myeloid Leukemia | Biotech Hunter | Biotech Hunter